CRISPR Therapeutics (CRSP) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) fell 2.9% on Thursday after an insider sold shares in the company. The company traded as low as $42.78 and last traded at $42.22. 282,558 shares ...

Shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) have been assigned a consensus recommendation of “Hold” from ...

Stock price predictions for 2025 are increasingly "meta." No, not the Facebook parent, but rather the idea that investments are increasingly self-referential rather than reliant on outside or ...

CRSP Stock’s Performance, Valuation & Estimates Shares of CRISPR Therapeutics have plunged nearly 40% in the past year compared with the industry’s 9% decline, as seen in the chart below.

CRISPR Therapeutics AG (CRSP) has been one of the most searched ... trends in earnings estimate revisions and short-term stock price movements. For the current quarter, CRISPR Therapeutics is ...